GBM patients with high PD-L1/PD-L2 harbored a statistically significant decreased DFS compared to patients who harbored both low expression levels (both high vs. both low: HR, 95% CI = 1.95, 1.21~3.15, log rank test P = 0.0072). The gene discussed is CD274; the disease is glioblastoma.